Page 1 - Diamicron MR MIG Cycle 2(20-21) Final

Dear Colleagues,

At the end of Dec 2020, nearly 1.3 million units of Diamicron MR were sold in MAT
growing with a strong double digit of +17%. And we are also growing in +11.3% in YTD Dec
2020, but we are losing our dynamism, achieving 94.5% YTD Dec 2020.

As you all know that we are amidst Covid-19 Pandemic, most of the doctors limit their
patients and practicing time effecting in prescription channel. Thus why, we couldn’t make
more new patients, but we maintained our old patients.

In addition to the changes of Pandemic, I would like to tell you more about the
diabetes market.

1. Our main competitor, DPP-4i especially with Metformin combinations growing
faster than market
2. Half of the gliclazide patients are taking generics
3. Strong penetration of SGLT-2i with strong cardiovascular benefits because of the
TAEs endorsement

Diamicron MR’s main theme is “Gain your Control at 7%” and as far as we highlight
the importance of getting HbA1c control as the most fundamental thing in management of
Diabetes, we have a huge potential for Diamicron MR.

We delivered our messages to the doctors remotely including the doctors who are
difficult to meet physically and they are appreciated for connecting them. We should take
these advantages of remote communication not only in the Covid-19 situation but also in the
normal daily situations.

In the last cycle, we organized lots of interactive scientific activities including the
focused group webinars specifically on CPRD and DIA-RAMADAN studies with nationwide
st
coverage. And we also organized 1 ever Cardio-Metabolic Virtual Scientific Summit which
was innovative and full of scientific knowledge. Plus, we participated in DAR conference and
Diabetes Summit. We put a lot of effort in these activities and all we have to do is to make
face to face follow up as much as possible with maximum effort.

I do believe that we will regain Diamicron MR’s dynamism in the coming cycle.

We Believe, We Will Achieve

Pyae Phyo Thant